|
| |
|
 |
| |
| BOARD OF DIRECTORS |
Carl C. Icahn
Chairman, ImClone Systems Incorporated
Portfolio Manager, Icahn Partners |
Alexander J. Denner, Ph.D.
Managing Director, Icahn Partners LP and
Icahn Partners Master Fund LP |
Thomas F. Deuel, M.D.
Professor, Molecular and Experimental Medicine and Cell Biology
Director, Division of Molecular Oncology, Department of Molecular and Experimental Medicine
Director, Vascular Biology Affinity Group, The Scripps Research Institute |
Jules Haimovitz
Vice Chairman and Managing Partner, Dick Clark Productions |
John H. Johnson
Chief Executive Officer
ImClone Systems Incorporated |
|
Peter S. Liebert, M.D
Chief, Pediatric Surgery
of The Stamford Hospital |
Richard Mulligan, Ph.D.
Mallinckrodt Professor of Genetics, Harvard Medical School
Director, Harvard Gene Therapy Initiative |
David Sidransky, M.D.
Professor of Otolaryngology, Oncology, Urology, Genetics, Pathology, and Cellular and Molecular Medicine
Director Head and Neck Cancer Research
Johns Hopkins University |
Charles Woler, M.D., Ph.D.
CEO, Neuro3D
Operating Partner Healthcare, Duke Street Capital |
|
| EXECUTIVE COMMITTEE |
Alexander J. Denner, Ph.D.
Chairman, Executive Committee
Managing Director, Icahn Partners LP and
Icahn Partners Master Fund LP |
|
Richard Mulligan, Ph.D.
Mallinckrodt Professor of Genetics, Harvard Medical School
Director, Harvard Gene Therapy Initiative |
|
|
|
